Table 3 Signal strength of hydroxyurea reports at the top 30 preferred term (PT) levels
PT | N | ROR (95%Cl) | PRR (χ2) | EBGM (EBGM05) | IC (IC025) |
|---|---|---|---|---|---|
Skin ulcer | 150 | 769.35 (228.58–2589.46) | 769.13 (2001.21) | 668.94 (242.3) | 9.39 (7.83) |
Anaemia | 137 | 569.89 (172.86–1878.83) | 569.72 (1532.86) | 512.85 (189.01) | 9 (7.47) |
Thrombocytopenia | 101 | 526.3 (335.76–824.98) | 525.26 (9967.45) | 476.54 (327.16) | 8.9 (8.25) |
Platelet count increased | 95 | 399.77 (174.15–917.7) | 399.55 (2212.87) | 370.74 (184.97) | 8.53 (7.4) |
Dysphagia | 80 | 349.7 (108.57–1126.4) | 349.6 (976.26) | 327.35 (123.01) | 8.35 (6.85) |
Pancytopenia | 75 | 314.02 (97.86–1007.61) | 313.93 (881.81) | 295.88 (111.54) | 8.21 (6.71) |
Platelet count decreased | 73 | 307.74 (95.97–986.8) | 307.65 (865.06) | 290.29 (109.5) | 8.18 (6.69) |
Interstitial lung disease | 71 | 263.05 (96.29–718.62) | 262.95 (992.9) | 250.17 (107.9) | 7.97 (6.64) |
Acute myeloid leukaemia | 58 | 260.79 (81.74–832.07) | 260.72 (738.62) | 248.15 (94) | 7.96 (6.47) |
Malignant neoplasm progression | 54 | 256.45 (80.42–817.81) | 256.38 (726.8) | 244.22 (92.54) | 7.93 (6.44) |
Haemoglobin decreased | 52 | 252.24 (79.13–804.04) | 252.17 (715.35) | 240.4 (91.13) | 7.91 (6.42) |
Febrile neutropenia | 50 | 229.66 (72.22–730.26) | 229.59 (653.52) | 219.79 (83.49) | 7.78 (6.3) |
Squamous cell carcinoma | 47 | 216.72 (68.25–688.16) | 216.66 (617.87) | 207.91 (79.07) | 7.7 (6.22) |
White blood cell count increased | 46 | 117.37 (55.47–248.35) | 117.3 (789.09) | 114.7 (61.26) | 6.84 (5.81) |
Sickle cell anaemia with crisis | 46 | 95.63 (71.16–128.51) | 95.23 (4119.43) | 93.51 (73.03) | 6.55 (6.12) |
Actinic keratosis | 45 | 87.92 (28.08–275.31) | 87.9 (253.39) | 86.44 (33.26) | 6.43 (4.97) |
Splenomegaly | 41 | 83.65 (37.33–187.45) | 83.6 (481.82) | 82.28 (41.88) | 6.36 (5.26) |
Foetal exposure during pregnancy | 40 | 81.13 (40.34–163.16) | 81.07 (622.8) | 79.82 (44.49) | 6.32 (5.35) |
Stomatitis | 40 | 70.66 (29.23–170.82) | 70.63 (338.54) | 69.68 (33.29) | 6.12 (4.93) |
Basal cell carcinoma | 39 | 65.05 (38.38–110.24) | 64.96 (870.7) | 64.16 (41.27) | 6 (5.25) |
Respiratory failure | 38 | 63.7 (36.04–112.6) | 63.63 (730.69) | 62.86 (39.03) | 5.97 (5.17) |
Tumour lysis syndrome | 38 | 59.47 (22.19–159.39) | 59.45 (227.23) | 58.78 (25.76) | 5.88 (4.58) |
Squamous cell carcinoma of skin | 36 | 54.77 (24.5–122.47) | 54.74 (313.22) | 54.17 (27.63) | 5.76 (4.66) |
Mucosal inflammation | 35 | 54.3 (37.4–78.83) | 54.16 (1445.72) | 53.6 (39.24) | 5.74 (5.2) |
Pleural effusion | 30 | 53.5 (35.46–80.72) | 53.39 (1170.21) | 52.85 (37.46) | 5.72 (5.13) |
Cerebral infarction | 29 | 47.64 (15.28–148.51) | 47.62 (135.68) | 47.19 (18.23) | 5.56 (4.11) |
Myelofibrosis | 28 | 47.32 (19.61–114.18) | 47.3 (224.55) | 46.88 (22.43) | 5.55 (4.37) |
Impaired healing | 27 | 47.06 (19.51–113.55) | 47.04 (223.27) | 46.62 (22.31) | 5.54 (4.36) |
Mouth ulceration | 24 | 46.49 (14.91–144.9) | 46.47 (132.29) | 46.06 (17.79) | 5.53 (4.07) |
Myelodysplastic syndrome | 23 | 45.88 (28.45–73.98) | 45.81 (738.49) | 45.41 (30.44) | 5.5 (4.82) |